Cassava Sciences Inc (SAVA) - Financial and Strategic SWOT Analysis Review

October 2021 | 48 pages | ID: CDFD9726309EN
GlobalData

Abstracts

Cassava Sciences Inc (SAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Cassava Sciences Inc (Cassava Sciences), formerly Pain Therapeutics Inc, is a clinical-stage biopharmaceutical company that develops drugs for the treatment of neuroinflammation and neurodegenerative diseases, with a special focus on Alzheimer’s disease. The company’s lead product candidate PTI-125 is a small molecule being developed in phase IIb clinical trials for treatment of Alzheimer’s disease. It is also investigating SavaDx, a blood-based diagnostic for detection of Alzheimer's disease. Cassava Sciences is headquartered in Austin, Texas, the US.

Cassava Sciences Inc Key Recent Developments

Sep 09,2021: Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
Aug 25,2021: Cassava Sciences responds to allegations
Aug 03,2021: Cassava Sciences Reports Second Quarter 2021 Financial Results
Jun 21,2021: Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release
Jun 14,2021: Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Cassava Sciences Inc - Key Facts
Cassava Sciences Inc - Key Employees
Cassava Sciences Inc - Key Employee Biographies
Cassava Sciences Inc - Major Products and Services
Cassava Sciences Inc - History
Cassava Sciences Inc - Company Statement
Cassava Sciences Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Cassava Sciences Inc - Business Description
R&D Overview
Cassava Sciences Inc - Corporate Strategy
Cassava Sciences Inc - SWOT Analysis
SWOT Analysis - Overview
Cassava Sciences Inc - Strengths
Cassava Sciences Inc - Weaknesses
Cassava Sciences Inc - Opportunities
Cassava Sciences Inc - Threats
Cassava Sciences Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cassava Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cassava Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cassava Sciences Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 09, 2021: Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
Aug 25, 2021: Cassava Sciences responds to allegations
Aug 03, 2021: Cassava Sciences Reports Second Quarter 2021 Financial Results
Jun 21, 2021: Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release
Jun 14, 2021: Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors
Apr 27, 2021: Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
Apr 26, 2021: Cassava Sciences to Participate in Sachs 4th Annual Neuroscience Innovation Forum
Mar 23, 2021: Cassava Sciences announces Full-year 2020 Financial Results and Business Highlights
Mar 08, 2021: Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 23, 2021: Cassava Sciences to Present at SVB Leerink Global Healthcare Conference

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Cassava Sciences Inc, Key Facts
Cassava Sciences Inc, Key Employees
Cassava Sciences Inc, Key Employee Biographies
Cassava Sciences Inc, Major Products and Services
Cassava Sciences Inc, History
Cassava Sciences Inc, Key Competitors
Cassava Sciences Inc, Ratios based on current share price
Cassava Sciences Inc, Annual Ratios
Cassava Sciences Inc, Annual Ratios (Cont...1)
Cassava Sciences Inc, Interim Ratios
Cassava Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cassava Sciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Cassava Sciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Cassava Sciences Inc, Performance Chart (2016 - 2020)
Cassava Sciences Inc, Ratio Charts
Cassava Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Cassava Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021